- Home
- NLSP vs IBO Comparison
NLSP vs IBO Comparison
Compare NLSP & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- IBO
- Stock Information
- Founded
- NLSP 2015
- IBO 2018
- Country
- NLSP Switzerland
- IBO United States
- Employees
- NLSP N/A
- IBO N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- IBO
- Sector
- NLSP Health Care
- IBO
- Exchange
- NLSP Nasdaq
- IBO NYSE
- Market Cap
- NLSP 5.8M
- IBO 5.1M
- IPO Year
- NLSP 2021
- IBO 2024
- Fundamental
- Price
- NLSP $2.30
- IBO $0.47
- Analyst Decision
- NLSP
- IBO
- Analyst Count
- NLSP 0
- IBO 0
- Target Price
- NLSP N/A
- IBO N/A
- AVG Volume (30 Days)
- NLSP 423.9K
- IBO 505.9K
- Earning Date
- NLSP 06-17-2025
- IBO 06-13-2025
- Dividend Yield
- NLSP N/A
- IBO N/A
- EPS Growth
- NLSP N/A
- IBO N/A
- EPS
- NLSP N/A
- IBO N/A
- Revenue
- NLSP N/A
- IBO N/A
- Revenue This Year
- NLSP N/A
- IBO N/A
- Revenue Next Year
- NLSP N/A
- IBO N/A
- P/E Ratio
- NLSP N/A
- IBO N/A
- Revenue Growth
- NLSP N/A
- IBO N/A
- 52 Week Low
- NLSP $1.30
- IBO $0.37
- 52 Week High
- NLSP $18.39
- IBO $6.17
- Technical
- Relative Strength Index (RSI)
- NLSP 65.15
- IBO N/A
- Support Level
- NLSP $1.58
- IBO N/A
- Resistance Level
- NLSP $2.39
- IBO N/A
- Average True Range (ATR)
- NLSP 0.23
- IBO 0.00
- MACD
- NLSP 0.02
- IBO 0.00
- Stochastic Oscillator
- NLSP 89.29
- IBO 0.00
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.